36766437|t|Application of the AT(N) and Other CSF Classification Systems in Behavioral Variant Frontotemporal Dementia.
36766437|a|BACKGROUND: Patients with a frontotemporal lobar degeneration (FTLD) usually manifest with behavioral variant frontotemporal dementia (bvFTD). Alzheimer's disease (AD) may also manifest with a predominant behavioral-dysexecutive syndrome, similar to bvFTD. Cerebrospinal fluid (CSF) biomarkers, such as total tau (tauT), phosphorylated tau (tauP-181) and amyloid beta with 42 amino-acids (Abeta42), can predict AD pathology in vivo. The aim of this study was to compare the tauT/Abeta42 and tauP-181/Abeta42 ratios, the BIOMARKAPD/ABSI criteria and the AT(N) classification system in a cohort of bvFTD patients. METHODS: A total of 105 bvFTD patients (21 possible bvFTD; 20%) with CSF data, examined from 2008 to 2022, were included. Seventy-eight AD patients and 62 control subjects were included. The CSF biomarkers were measured with Innotest (2008-2017 subcohort) and EUROIMMUN (2017-2022 subcohort) ELISAs. RESULTS: Depending on the classification system, 7.6 to 28.6% of bvFTD had an AD biochemical profile. The tauT/Abeta42 and tauP-181/Abeta42 ratios classified more patients as AD compared to the BIOMARKAPD/ABSI and AT(N) systems. The patients with possible bvFTD had higher frequencies of AD compared to the probable bvFTD patients. CONCLUSIONS: The four classification criteria of CSF AD biomarkers resulted in differences in AD allocation in this bvFTD cohort. A consensus on the optimal classification criteria of CSF AD biomarkers is pivotal.
36766437	19	21	AT	Disease	
36766437	65	107	Behavioral Variant Frontotemporal Dementia	Disease	MESH:D057180
36766437	121	129	Patients	Species	9606
36766437	137	170	frontotemporal lobar degeneration	Disease	MESH:D057174
36766437	172	176	FTLD	Disease	MESH:D057174
36766437	200	242	behavioral variant frontotemporal dementia	Disease	MESH:D057180
36766437	244	249	bvFTD	Disease	MESH:D057180
36766437	252	271	Alzheimer's disease	Disease	MESH:D000544
36766437	273	275	AD	Disease	MESH:D000544
36766437	314	346	behavioral-dysexecutive syndrome	Disease	MESH:D001523
36766437	359	364	bvFTD	Disease	MESH:D057180
36766437	418	421	tau	Gene	4137
36766437	423	427	tauT	Gene	6533
36766437	445	448	tau	Gene	4137
36766437	498	505	Abeta42	Gene	351
36766437	520	522	AD	Disease	MESH:D000544
36766437	583	587	tauT	Gene	6533
36766437	588	595	Abeta42	Gene	351
36766437	609	616	Abeta42	Gene	351
36766437	662	664	AT	Disease	
36766437	705	710	bvFTD	Disease	MESH:D057180
36766437	711	719	patients	Species	9606
36766437	745	750	bvFTD	Disease	MESH:D057180
36766437	751	759	patients	Species	9606
36766437	773	778	bvFTD	Disease	MESH:D057180
36766437	857	859	AD	Disease	MESH:D000544
36766437	860	868	patients	Species	9606
36766437	1086	1091	bvFTD	Disease	MESH:D057180
36766437	1099	1101	AD	Disease	MESH:D000544
36766437	1127	1131	tauT	Gene	6533
36766437	1132	1139	Abeta42	Gene	351
36766437	1153	1160	Abeta42	Gene	351
36766437	1184	1192	patients	Species	9606
36766437	1196	1198	AD	Disease	MESH:D000544
36766437	1235	1237	AT	Disease	
36766437	1254	1262	patients	Species	9606
36766437	1277	1282	bvFTD	Disease	MESH:D057180
36766437	1309	1311	AD	Disease	MESH:D000544
36766437	1337	1342	bvFTD	Disease	MESH:D057180
36766437	1343	1351	patients	Species	9606
36766437	1406	1408	AD	Disease	MESH:D000544
36766437	1447	1449	AD	Disease	MESH:D000544
36766437	1469	1474	bvFTD	Disease	MESH:D057180
36766437	1541	1543	AD	Disease	MESH:D000544
36766437	Association	MESH:D000544	4137
36766437	Association	MESH:D000544	6533
36766437	Association	MESH:D000544	351

